CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Assier, France

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

    This is a single arm, phase II clinical trial designed to assess the impact of tumor and stromal molecular subtypes on the efficacy of neoadjuvant FOLFIRNOX in untreated subjects with resectable, borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma (PDAC). Subjects will undergo an EUS-guided core biopsy of the pancreas prior to treatment and after cycle 8 of FOLFIRINOX. Imaging will be performed after every 4 cycles of chemotherapy (8 weeks) and reassessed for resectability after 12 cycles. If patients show a response to treatment that is deemed by the surgical oncologist to be amenable to resection, surgery can be pursued after 8 cycles of therapy. In this case, the remaining 4 cycles of treatment will be given after surgery. Duration of Therapy: In the absence of treatment delays due to adverse events, treatment may continue until: - Disease progression, - Inter-current illness that prevents further administration of treatment, - Unacceptable adverse event(s), - Subject decides to withdraw from the study, or - General or specific changes in the subject's condition render the subject unacceptable for further treatment in the judgment of the investigator. Duration of Follow Up: - Subjects will be followed for 36 months after removal from study treatment or until death, whichever occurs first. Subjects removed from study treatment for unacceptable adverse events will be followed until resolution or stabilization of the adverse event.

    Phase

    2

    Span

    556 weeks

    Sponsor

    UNC Lineberger Comprehensive Cancer Center

    Recruiting

  • HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

    This is a multicenter, randomized, controlled, open-label study including patients with localized and locally advanced diffuse and mixed type adenocarcinoma of the stomach and Type II/III GEJ scheduled to receive perioperative chemotherapy combined with intraoperative HIPEC procedure. The scope of the trial is to evaluate the efficacy as well as the safety and tolerability of the combination of perioperative chemotherapy combined with an intraoperative HIPEC for resectable diffuse and mixed type gastric and GEJ (types II/III) adenocarcinoma. Intraoperative hyperthermic chemoperfusion is summarized under the abbreviation HIPEC in the following. Patients with localized and locally advanced diffuse or mixed type adenocarcinoma of the stomach and Type II/III GEJ (i.e. ≥cT3 any N or any T N-positive) with exclusion of distant metastases and after receiving neoadjuvant FLOT- therapy will be included in this trial after a central review. All enrolled patients will have received 3-6 pre-operative cycles (de-escalation or dose modification allowed) of biweekly FLOT (Docetaxel 50 mg/m² in 250 ml NaCl 0.9%, iv over 1 h; Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h; Leucovorin 200 mg/m² in 250 ml NaCl 0.9%, iv over 30 min; 5-FU 2600 mg/m², iv over 24 h, q2wk) in the preoperative treatment phase. After completion of neoadjuvant FLOT- therapy followed by pre-operative tumor assessment, (also including diagnostic laparoscopy prior to start of FLOT), patients without disease progression (expected to be approximately 90% of the patients) will be included into the trial, stratified by initial clinical stage (N- vs. N+), histological type of tumor (Lauren classification diffuse vs. mixed) and study site. Patients will be randomized 1:1 to receive either postoperative FLOT (Arm A) or postoperative FLOT + intraoperative HIPEC (Arm B). Arm A (FLOT) Surgery in Arm A is planned to occur 4 to 6 weeks after d1 of last FLOT. Surgery is carried out in kind of gastrectomy, transhiatal extended gastrectomy. Following surgery, patients will receive four further 2-week treatment cycles FLOT in the post-operative treatment phase. Post-operative treatment should start 6 to 8 weeks, but at maximum 12 weeks after surgery. Arm B (FLOT/ HIPEC) Surgery in Arm B is planned to occur 4 to 6 weeks after d1 of last FLOT. Surgery is carried out in kind of gastrectomy, transhiatal extended gastrectomy. Surgery will be combined with an intraoperative Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) including cisplatin solution administered at a temperature of 42°C for 90 minutes. Following surgery, patients will receive four further 2-week treatment cycles FLOT in the post-operative treatment phase. Post-operative treatment should start 6 to 8 weeks, but at maximum 12 weeks after surgery. In both of the arms, tumor assessments (CT or MRI) are performed before randomization prior to surgery, and then every 3 months (radiological tumor assessment) thereafter until progression/relapse, death or end of follow-up. A change from CT into MRI in the follow up period is possible at any time. During treatment, clinical visits (blood cell counts, detection of toxicity) occur prior to every treatment dose. Safety of FLOT/ HIPEC will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs) reported. The phase III design starts with a safety run-in phase. After 20 patients had curatively intended resection in Arm B, an interim safety analysis is performed that shows feasibility, safety, and tolerability of Arm B planned at the time 8 weeks after the 20th patient in Arm B had curatively intended resection. It is not planned to discontinue recruitment for the interim safety analysis.

    Phase

    3

    Span

    333 weeks

    Sponsor

    Krankenhaus Nordwest

    Recruiting

  • Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

    Phase

    1

    Span

    369 weeks

    Sponsor

    University of Chicago

    Recruiting

  • Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

    PRIMARY OBJECTIVES: I. To evaluate the safety, tolerability and resection rate (for borderline resectable pancreatic cancer [BRPC] cohort) or progression free survival (PFS) (for locally advanced pancreatic cancer [LAPC] cohort) in patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) treated with modified fluorouracil, irinotecan, leucovorin and oxaliplatin (mFOLFIRINOX), quemliclustat, and zimberelimab. II. To evaluate development of clinically relevant pancreatic fistula (for BRPC cohort) in the post-operative period after neoadjuvant treatment with mFOLFIRINOX, quemliclustat, and zimberelimab. SECONDARY OBJECTIVES: I. To estimate efficacy as measured by decreases in CA 19-9 and objective response rate (ORR) by imaging (unconfirmed complete and partial responses). II. To estimate the pathologic complete response rate (pCR) (for BRPC cohort) and overall survival (OS). EXPLORATORY OBJECTIVES: I. To evaluate the effects of zimberelimab, quemliclustat, and modified FOLFIRINOX (mFFX) on the tumor-stromal cells comparing pre-treatment core biopsies with operative specimens and on the effects on T cell infiltration, PD1 expression and the tumor microenvironment (TME). II. To investigate potential serum and tumor predictive biomarkers to predict response to experimental therapy. OUTLINE: Patients receive zimberelimab intravenously (IV), quemliclustat IV, oxaliplatin IV, leucovorin calcium IV, and inrinotecan IV on study. Patients undergo collection of blood samples and computed tomography (CT) throughout the trial. Patients with borderline-resectable pancreatic cancer undergo collection of tissue samples. Patients with locally advanced pancreatic cancer undergo core biopsy.

    Phase

    1/2

    Span

    156 weeks

    Sponsor

    Jonsson Comprehensive Cancer Center

    Recruiting

  • Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

    Phase

    2

    Span

    225 weeks

    Sponsor

    H. Lee Moffitt Cancer Center and Research Institute

    Recruiting

  • Botensilimab and Balstilimab Optimization in Colorectal Cancer

    3.1 Study Description This is a single-arm, interventional, pilot clinical trial. Subjects with newly diagnosed, metastatic or unresectable, microsatellite stable colorectal cancer without liver, bone, or brain metastases will undergo tumor-informed ctDNA collection then start study treatment with botensilimab and balstilimab alone. They will have restaging scans every 12 weeks and will have ctDNA and CEA repeated at every cycle. When the subject experiences radiographic progression per RECIST/iRECIST or clinical progression per investigator's assessment, mFOLFOX6 and either bevacizumab or panitumumab will be added to the study drug regimen. Subject will continue on the new combination until radiographic or clinical progression, intolerable toxicity, or patient withdrawal. No more than 20 subjects will be enrolled to ensure the trial obtains 15 evaluable subjects. All patients will be enrolled at the Duke Cancer Institute. - Enrolled subjects are defined as subjects who give informed consent. - Screen failures are defined as subjects who give informed consent and do not meet eligibility criteria. - Accrued subjects are defined as subjects who give informed consent and meet eligibility criteria. - Withdrawal: Subject accrued but later withdrawn from the study, either before or after receiving a study drug. - Evaluable: All subject who are accrued, receive all Cycle 1 study treatment with botensilimab and balstilimab, and complete the first cycle of safety assessments will be considered evaluable for the primary endpoints for disease control rate, best overall response, and safety. - Non-evaluable: Subjects who accrued but did not complete the first cycle of safety assessments due to reasons other than study treatment-attributed toxicity (e.g., disease progression or inter-current illness) are considered non-evaluable for safety and efficacy. Study Treatment Botensilimab 75 mg IV Every 6 weeks for up to 4 doses Balstilimab 240 mg IV Every 2 weeks Oxaliplatin 85 mg/m2 IV Every 2 weeks Leucovorin 400 mg/m2 IV Every 2 weeks Fluorouracil 400 mg/m2 IV bolus Every 2 weeks Fluorouracil 2400 mg/m2 IV Every 2 weeks (over 46 hours) Bevacizumab 5 mg/kg IV Every 2 weeks Panitumumab 6 mg/kg IV Every 2 weeks 5.1 Screening Period During the screening period, subjects are consented and screened for the study. Informed consent must be obtained before initiation of any screening procedure that is performed solely for the purpose of determining eligibility for this study. Evaluations performed as part of routine care before informed consent can be considered as screening evaluations if done within the defined screening period, and if permitted by the local institutional review board (IRB) policies. Study eligibility is based on meeting all of the inclusion criteria and none of the exclusion criteria before the first dose of study drug on Cycle 1 Day 1. The following study procedures must be done within 28 days prior to Cycle 1 Day 1: - Inclusion and exclusion criteria - Demographics - Medical and cancer history - Physical examination - Height - Vital signs and weight - Concomitant medications - CT and/or MRI of chest, abdomen, and pelvis - ctDNA - CEA - PT/INR (prior to fresh tissue biopsy) - Fresh tissue biopsy - Archived tissue collection - Tuberculosis (TB) test - NOTE: skin test is not allowed. Interferon-Gamma Release Assay (IGRA)-based tests such as QuantiFERON TB Gold and T-Spot TB tests are acceptable. The following study procedures must be done or repeated within 7 days prior to Cycle 1 Day 1: - CBC with differential - CMP - TSH and fT4 - Pregnancy test (only for women of childbearing potential) Subject eligibility is determined using lab results obtained up to 7 days prior to Cycle 1 Day 1. Any laboratory assessments repeated on Cycle 1 Day 1 must meet eligibility requirements. The screening period ends upon receipt of the first dose of study drug or final determination that the subject is ineligible for the study. 5.2 Treatment Period During the treatment period, subjects will receive botensilimab every 6 weeks for up to 4 doses and balstilimab every 2 weeks for up to 2 years. Following progression on the doublet, mFOLFOX6 will be administered every 2 weeks. Investigators will choose between bevacizumab and panitumumab, which will be administered every 2 weeks. Cycle length is every 6 weeks, with study visits occurring every 2 weeks. A treatment window of ± 1 day is allowed for day 1 of cycle 2 and all subsequent cycles. The treatment period lasts until: 1) subject has been receiving balstilimab for 2 years; 2) disease progression; 3) the occurrence of unacceptable treatment-attributed toxicity; or 4) other reasons for subject discontinuation as described in Section 5.7. Toxicity-attributed dose modifications of any of the study drugs may occur during the Treatment Period. After the completion of the first cycle, laboratory assessments may be obtained up to 1 day prior to treatment. If necessary, the treatment visit may be within ± 1 day of the scheduled day 1 for cycle 2 and all subsequent cycles. If clinically indicated, additional visits and/or safety assessments may be warranted. The following study procedures must be completed on days 1, 15, and 29 of each cycle: - Concomitant medications - Physical examination - Vital signs and weight - ECOG performance status - CBC with differential - CMP - Administer balstilimab - Administer mFOLFOX6 - Administer bevacizumab (if applicable) - Administer panitumumab (if applicable) - Adverse event assessment The following study procedures must be added to the above test/procedures on Day 1 of each cycle: - ctDNA - CEA - Administer botensilimab (maximum 4 doses) - Plasma for biomarker analysis (prior to treatment on C1D1 and C3D1 only) The following study procedures must be completed every 12 weeks (±1 week): - Thyroid function tests (TSH and fT4) - Tumor assessment (CT and/or MRI scans) The following study procedures must be completed at time of progression on doublet therapy (any time prior to the start of chemotherapy administration): - Optional biopsy of the progressing lesion - PT/INR (only if doing biopsy, prior to biopsy) Restaging scans will be performed every 12 weeks and disease response will be assessed using guidelines described in Section 5.6. The treatment period ends when a subject receives his or her last dose of study treatment; the subject then enters the follow-up period. 5.3 Follow-up Period Subjects should return 30 (±7) days after their last dose of study drug for an end-of-treatment visit to complete the following study procedures: - Concomitant medications - Physical examination - Vital signs and weight - ECOG performance status - Adverse event assessment - CBC with differential - CMP - Thyroid profile (TSH and fT4) - Serum pregnancy test (only for women of childbearing potential) - ctDNA - CEA - Plasma for biomarker analysis Subjects will have a telephone visit with the study team at 90 (+/-7) days after the last dose of study drug to complete an AE assessment. Any delayed irAEs must be reported to the principal investigator. Subjects with adverse events (AEs) attributed to study drug that are ongoing at the time of this 90-day safety follow-up visit will continue to be followed unless the AE is deemed unresolvable or the subject has started a new anti-cancer treatment regimen. For subjects who are discontinued from study treatment for reasons other than disease progression, subjects will have disease status (blood tumor markers and restaging scans per standard of care schedule) followed until disease progression or start of new anti-cancer treatment regimen. Disease status may be collected via personal interviews or review of medical records. Subjects will be followed for survival up to 2 years after discontinuing the study drug regimen or until the study is closed (whichever comes first). Survival status may be collected by phone call or review of medical or public records every 12 (±2) weeks. 5.4 Laboratory Assessments Local laboratories will perform all clinical laboratory tests using standard procedures, and results will be provided to the investigator. Abnormalities in clinical laboratory tests that lead to a change in subject management (e.g., dose modification, requirement for additional medication, treatment or monitoring) are considered clinically significant for the purposes of this study and will be recorded on the case report form (CRF). If laboratory values constitute part of an event that meets criteria defining it as serious, the event (and associated laboratory values) must be reported as a serious adverse event (SAE). 5.5 Adverse Event Assessment AEs will be documented throughout the study. AE seriousness, grade, and relationship to study drug will be assessed by the investigator using NCI-CTCAE version 5.0. 5.6 Tumor Assessments Tumor response will be assessed using RECIST v.1.1 and iRECIST. Radiographic imaging will be performed with CT scan of chest/abdomen/pelvis with and without contrast and/or MRI scan of abdomen/pelvis every 12 weeks. The same method for tumor assessment should be employed at every assessment. 5.7 Subject Discontinuation Subjects will receive study treatment until treatment discontinuation for one of the reasons listed below. However, subjects may discontinue study treatment or withdraw their consent to participate in the study at any time without prejudice. All reasons for discontinuation or withdrawal from trial will be recorded. Subjects who progress on the initial doublet regimen do not have to discontinue study treatment at that time. Rather, they will add mFOLFOX6 and either bevacizumab or panitumumab and continue on study treatment. Patients who have complete response or prolonged stable disease may also elect to end study therapy after a discussion with their treating physician and with approval of the principal investigator. Reasons for subject discontinuation may include, but are not limited to, the following: - Subject has been receiving balstilimab for 2 years - Death - Confirmed radiographic disease progression after switching to the botensilimab and balstilimab plus chemo/bev/pmab - Subjects with radiographic disease progression who are continuing to derive clinical benefit from the regimen may be allowed to continue on treatment beyond radiographic progression if, in the opinion of the investigator, it is the best interests of the patient, and with the principal investigator's approval. - Significant noncompliance by subject or investigator - Investigator or principal investigator determination that it is no longer safe and/or no longer in the subject's best interest to continue participation - Withdrawal of consent - Loss to follow-up - Necessity for treatment with other anticancer treatment prohibited by protocol - Sexually active subjects who refuse to follow the contraceptive guidelines - Women who become pregnant or are breast feeding - Request by regulatory agencies for termination of treatment of an individual subject or all subjects under the protocol - Discontinuation of treatment may be considered for participants who have attained a confirmed complete response (CR)

    Phase

    2

    Span

    193 weeks

    Sponsor

    Nicholas DeVito, MD

    Recruiting

  • Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

    Phase

    N/A

    Span

    105 weeks

    Sponsor

    Tianjin Medical University Cancer Institute and Hospital

    Recruiting

  • FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

    PRIMARY OBJECTIVES: The goal of this prospective, randomized, controlled clinical trial is to evaluate the objective remission rate (ORR) of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with irinotecan with or without bevacizumab systemic intravenous chemotherapy versus systemic intravenous FOLFOXIRI with or without bevacizumab in initially unresectable RAS-mutated colorectal cancer patients with liver metastases. SECONDARY OBJECTIVES: To assess and compare the depth of response (DpR), R0 surgical resection rate, No evidence of disease (NED) rate, progression-free survival (PFS), overall survival (OS), recurrence-free survival (RFS) in resectable patients and safety (chemotherapy-related adverse events, catheterization-related adverse events, surgical complications, etc.) between the two intervention groups. OUTLINE: Patients in the HAI group receive FOLFOX via hepatic artery infusion chemotherapy plus intravenous irinotecan with or without bevacizumab every 14 days, while patients in the systemic group receive intravenous FOLFOXIRI regimen with or without bevacizumab every 14 days. Patients will receive a maximum of 12 cycles in total (before and after surgery) unless there is disease progression, unacceptable toxicity, or if the patient withdraws from the study.

    Phase

    2

    Span

    231 weeks

    Sponsor

    Sun Yat-sen University

    Recruiting

  • ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

    Primary Objective: • To assess 1-year recurrence-free survival rate following liver resection of CLM with curative intent among ctDNA-negative patients who receive risk-stratified postoperative chemotherapy Secondary Objectives: - To assess recurrence-free survival following liver resection of CLM with curative intent among ctDNA-positive patients - To assess overall survival following liver resection among ctDNA-negative and ctDNA-positive patients - To evaluate the proportion of ctDNA-negative at 1-year post-resection - To compare survival of ctDNA-negative patients undergoing ctDNA-guided postoperative chemotherapy to historical controls - To evaluate proportion of patients in each arm who change chemotherapy in response to ctDNA measurement - To delineate the pattern of disease recurrence - To assess ctDNA sensitivity and specificity for predicting disease recurrence - To evaluate MDASI-GI during the course of postoperative therapy - To evaluate and correlate patient molecular subtypes and characterization of tumor biologic factors that are associated with ctDNA detection - To evaluate surgery-related adverse events occurring up to 90 days after surgery, and chemo-related adverse events occurring up to 30 days after the last dose of chemotherapy Outcome Measures: Primary: • Recurrence-free survival at 1-year post-hepatectomy among ctDNA-negative patients Secondary: - Recurrence-free survival at 1-year post-hepatectomy among ctDNA-positive patients - Overall survival (OS) among ctDNA-negative and ctDNA-positive patients - ctDNA-negativity at 1-year post-resection - Proportion of patients in each group with chemotherapy regimen change in response to ctDNA dynamics - Pattern of disease recurrence (i.e., liver, systemic, salvageable vs. unsalvageable) - ctDNA sensitivity/specificity for recurrent disease overall by timepoint - MDASI-GI at clinic visits during course of postoperative therapy - Tumor radiologic, histologic, and molecular profiling and correlative characterization based upon ctDNA detection - Adverse events

    Phase

    2

    Span

    201 weeks

    Sponsor

    M.D. Anderson Cancer Center

    Recruiting

  • Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

    Phase

    3

    Span

    412 weeks

    Sponsor

    Erasmus Medical Center

    Recruiting

1-10 of 107
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information